Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.
Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL. Carvajal-Hausdorf DE, et al. Among authors: kalogeras kt. Clin Cancer Res. 2019 May 15;25(10):3054-3062. doi: 10.1158/1078-0432.CCR-18-2599. Epub 2019 Feb 22. Clin Cancer Res. 2019. PMID: 30796036 Free PMC article. Clinical Trial.
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Among authors: kalogeras kt. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G. Psyrri A, et al. Among authors: kalogeras kt. Ann Oncol. 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056852 Free article.
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA. Fountzilas G, et al. Among authors: kalogeras kt. BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163. BMC Cancer. 2013. PMID: 23537287 Free PMC article.
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G. Razis E, et al. Among authors: kalogeras kt. J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5. J Cancer Res Clin Oncol. 2014. PMID: 24595598
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G. Pavlakis K, et al. Among authors: kalogeras kt. Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2. Epub 2014 Aug 8. Pathol Oncol Res. 2015. PMID: 25098276 Free article.
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G. Koumarianou A, et al. Among authors: kalogeras kt. Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7. Cancer Chemother Pharmacol. 2015. PMID: 25947084
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G. Linardou H, et al. Among authors: kalogeras kt. Anticancer Res. 2015 Jul;35(7):4023-36. Anticancer Res. 2015. PMID: 26124351 Clinical Trial.
96 results